Search results for "coro"

showing 10 items of 3650 documents

Angiographic follow-up results of a randomized study on angioplasty versus bypass surgery (GABI Trial)

1996

Although several randomized trials have been performed to compare the outcomes of percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass surgery (CABG) in patients with multivessel disease, there is little data available on angiographic follow-up results. The present substudy of the German angioplasty versus bypass surgery investigation (GABI Trial) compares the angiographic revascularization status in these two cases 6 months after treatment. Follow-up angiograms were available in 102 CABG patients and 117 PTCA patients. Although the protocol excluded patients with total occlusion, on follow-up 6 months after treatment we found total occlusion of 94 native arterie…

medicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentRevascularizationlaw.inventionSurgeryLesionCoronary artery bypass surgerysurgical procedures operativeRandomized controlled trialBypass surgerylawInternal medicineAngioplastyAngiographyCardiologyMedicinecardiovascular diseasesDerivationmedicine.symptomCardiology and Cardiovascular MedicinebusinessEuropean Heart Journal
researchProduct

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

2020

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who hav…

medicine.medical_specialtymedicine.drug_classantithrombotic therapyCoronavirus disease 2019; SARS-CoV-2; anticoagulant; antiplatelet; antithrombotic therapy; thrombosisDisease030204 cardiovascular system & hematologyantiplateletPathogenesis03 medical and health sciences0302 clinical medicineAntithromboticEpidemiologyMedicine030212 general & internal medicinePlatelet activationEndothelial dysfunctionIntensive care medicinethrombosisCoronavirus disease 2019SARS-CoV-2business.industryanticoagulantAnticoagulantmedicine.diseaseThrombosisCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

Type 1 or Type 2 Myocardial Infarction in Patients with a History of Coronary Artery Disease: Data from the Emergency Department

2019

A type 2 myocardial infarction (T2MI) is the result of an imbalance between oxygen supply and demand, without acute atherothrombosis. T2MI is frequent in emergency departments (ED), but has not been extensively evaluated in patients with previously known coronary artery disease (CAD). Our study assessed the incidence and characteristics of T2MI compared to type 1 (T1MI) in CAD patients admitted to an ED. Among 33,669 consecutive patients admitted to the ED, 2830 patients with T1MI or T2MI were systematically included after prospective adjudication by the attending clinician according to the universal definition. Among them, 619 (22%) patients had a history of CAD. Using multivariable analys…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyArticletype 2 myocardial infarctionCoronary artery disease03 medical and health sciences0302 clinical medicineInternal medicinemedicine030212 general & internal medicineMyocardial infarctionhospital mortalitybiologybusiness.industryC-reactive proteinPercutaneous coronary interventionGeneral MedicineOdds ratioEmergency departmentmedicine.diseaseTroponinConfidence intervalmyocardial infarctionCardiologybiology.proteinbusinesscoronary artery diseaseJournal of Clinical Medicine
researchProduct

Impact of overlapping on 1-year clinical outcomes in patients undergoing everolimus-eluting bioresorbable scaffolds implantation in routine clinical …

2016

Background Overlapping implantation of bioresorbable scaffolds (BRSs) are frequent in long coronary lesions. Its impact on clinical outcomes is unknown. Objective: To compare the clinical outcomes of patients treated with overlapping BRS with those patients treated with no-overlap BRS. Methods: We analyzed the 1-year clinical outcomes of 1,477 patients treated with BRS in the GHOST-EU registry, according to the implantation of overlapping BRS. Primary endpoint was patient oriented composite endpoint (PoCE) of: all-cause death, any myocardial infarction (MI) and any repeated revascularization. Scaffold thrombosis, according to Academic Research Consortium definition, was also analyzed. Resul…

medicine.medical_specialtymedicine.medical_treatment030204 cardiovascular system & hematologyRevascularizationCoronary artery diseaseLesion03 medical and health sciences0302 clinical medicineInternal medicinemedicineClinical endpointRadiology Nuclear Medicine and imaging030212 general & internal medicineMyocardial infarctionEverolimusbusiness.industryfungiPercutaneous coronary interventionGeneral Medicinemedicine.diseaseThrombosisCardiologymedicine.symptomCardiology and Cardiovascular Medicinebusinessmedicine.drugCatheterization and Cardiovascular Interventions
researchProduct

Usefulness of Stress Echocardiography in the Management of Patients Treated with Anticancer Drugs.

2021

In recent years, the survival of patients with cancer has improved thanks to advances in antineoplastic therapeutic protocols. This has led to an increasing burden of cardiovascular complications related to cancer treatment. Therefore, a new branch of cardiology has been created, ``cardio-oncology,'' with the aims of preventing cardiovascular complications related to antineoplastic treatment, achieving early diagnosis and treatment of any complications, and allowing completion of the expected antineoplastic treatment. Stress echocardiography has a pivotal role in achieving a timely diagnosis of coronary artery disease and thus is the best management approach in this clinical setting. Athero…

medicine.medical_specialtymedicine.medical_treatmentAntineoplastic Agents030204 cardiovascular system & hematologyCoronary artery disease030218 nuclear medicine & medical imagingCoronary artery diseaseAntineoplastic Agent03 medical and health sciences0302 clinical medicineAntineoplastic therapeutic protocolsEchocardiography StreNeoplasmsAntineoplastic therapeutic protocolmedicineStress EchocardiographyHumansRadiology Nuclear Medicine and imagingIn patientCADIntensive care medicineAntineoplastic therapeutic protocols CAD Cardio-oncology Cardiotoxicity Coronary artery disease Stress echocardiography Cardiotoxicity Early Detection of Cancer Echocardiography Echocardiography Stress Humans Antineoplastic Agents NeoplasmsEarly Detection of CancerSubclinical infectionChemotherapyCardiotoxicitybusiness.industryCancerAntineoplastic therapeutic protocols; CAD; Cardio-oncology; Cardiotoxicity; Coronary artery disease; Stress echocardiographymedicine.diseaseCardiotoxicityCardio-oncologyStress echocardiographyAnticancer treatmentEchocardiographyCardiology and Cardiovascular MedicinebusinessHumanEchocardiography StressJournal of the American Society of Echocardiography : official publication of the American Society of Echocardiography
researchProduct

Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up☆

2021

Abstract Background Long-term effects of Coronavirus Disease of 2019 (COVID-19) are of utmost relevance. We aimed to determine: 1) the functional capacity of COVID-19 survivors by cardiopulmonary exercise testing (CPET); 2) the characteristics associated with cardiopulmonary exercise testing (CPET) performance; 3) the safety and tolerability of CPET. Methods We prospectively enrolled consecutive patients with laboratory-confirmed COVID-19 from Azienda Sanitaria Locale 3, Genoa. Three months after hospital discharge a complete clinical evaluation, trans-thoracic echocardiography, CPET, pulmonary function tests, and dominant leg extension (DLE) maximal strength measurement were performed. Res…

medicine.medical_specialtymedicine.medical_treatmentBacterial ToxinsArticlePulmonary function testingCardiopulmonary exercise testing; Coronavirus; Coronavirus infection; COVID-19; Lung diseases; Severe acute respiratory syndrome; Echocardiography; Exercise Tolerance; Follow-Up Studies; Humans; Oxygen Consumption; SARS-CoV-2; COVID-19; Exercise TestOxygen ConsumptionInternal medicineDiffusing capacityCoronavirus infectionMedicineHumansSurvivorsAdverse effectLung diseasesRehabilitationExercise Tolerancebusiness.industrySARS-CoV-2VO2 maxCOVID-19Cardiopulmonary exercise testingCoronavirusTolerabilitySevere acute respiratory syndromeEchocardiographyCohortExercise TestCardiology and Cardiovascular MedicinebusinessAnaerobic exerciseFollow-Up StudiesInternational Journal of Cardiology
researchProduct

Management of refractory angina: an update.

2020

Abstract Despite the use of anti-anginal drugs and/or percutaneous coronary interventions (PCI) or coronary artery bypass grafting, the proportion of patients with coronary artery disease who have daily or weekly angina ranges from 2% to 24%. Refractory angina refers to long-lasting symptoms (for >3 months) due to established reversible ischaemia, which cannot be controlled by escalating medical therapy with the use of 2nd- and 3rd-line pharmacological agents, bypass grafting, or stenting. While there is uncertain prognostic benefit, the treatment of refractory angina is important to improve the quality of life of the patients affected. This review focuses on conventional pharmacolog…

medicine.medical_specialtymedicine.medical_treatmentChronic coronary syndromeStemcell therapyCoronary Artery Disease030204 cardiovascular system & hematologyRevascularizationAngina PectorisAnginaCoronary artery disease03 medical and health sciencesCoronary artery bypass surgery0302 clinical medicinePercutaneous Coronary InterventionRestenosisInternal medicinemedicineMyocardial RevascularizationHumanscardiovascular diseases030212 general & internal medicineCoronary Artery BypassCoronary sinusbusiness.industryPercutaneous coronary interventionAnginamedicine.diseaseRadiation therapyChronic total occlusionSpinal cord stimulationConventional PCICardiologyQuality of LifeCardiology and Cardiovascular MedicinebusinessEuropean heart journal
researchProduct

Appropriateness of percutaneous revascularization of coronary chronic total occlusions: an overview

2016

Coronary chronic total occlusions (CTOs) are commonly encountered in patients undergoing coronary angiography. Several observational studies have demonstrated that successful CTO revascularization is associated with better cardiovascular outcomes and enhanced quality of life (QOL). However, in the absence of randomized trials, its prognostic benefit for patients remains debated. Over the past decade, the interest of the interventional community in CTO percutaneous coronary intervention (PCI) has exponentially grown due to important developments in dedicated equipment and techniques, resulting in high success and low complication rates. Both European and American guidelines have assigned a c…

medicine.medical_specialtymedicine.medical_treatmentCoronary OcclusionTreatment OutcomeGuideline030204 cardiovascular system & hematologyRevascularizationlaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicineRandomized controlled trialQuality of lifelawCTO; PCIInternal medicinemedicineHumans030212 general & internal medicineIntensive care medicineCardiovascular outcome; Chronic total occlusion; Guidelines; PCI; Quality of life; Chronic Disease; Humans; Percutaneous Coronary Intervention; Quality of Life; Treatment Outcome; Coronary Occlusion; Cardiology and Cardiovascular Medicinebusiness.industryPercutaneous coronary interventionPCICardiovascular outcomeEvidence-based medicineCTOChronic total occlusionTreatment OutcomeCoronary OcclusionCoronary occlusionChronic DiseaseConventional PCIQuality of LifeCardiologyObservational studyCardiology and Cardiovascular MedicinebusinessHumanEuropean Heart Journal
researchProduct

Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRAIL Clinical Trial Study Design

2019

Abstract Introduction and objectives Although clinical guidelines recommend invasive management in non–ST-segment elevation myocardial infarction (NSTEMI), this strategy is underused in frail elderly patients in the real world. Furthermore, these patients are underrepresented in clinical trials and therefore the evidence is scarce. Our hypothesis is that an invasive strategy will improve prognosis in elderly frail patients with NSTEMI . Methods This will be a prospective, multicenter, randomized trial, in which the conservative and invasive strategies will be compared in patients meeting all of the following inclusion criteria: NSTEMI diagnosis, age ≥ 70 years, and frailty defined by a cate…

medicine.medical_specialtymedicine.medical_treatmentFrail ElderlyAcute myocardial infarction030204 cardiovascular system & hematologyRevascularizationConservative TreatmentCoronary Angiographylaw.invention03 medical and health sciences0302 clinical medicineElderlyRandomized controlled triallawmedicineClinical endpointMyocardial RevascularizationHumansMulticenter Studies as TopicFrail elderlyMyocardial infarctionProspective StudiesProspective cohort studyNon-ST Elevated Myocardial InfarctionAgedRandomized Controlled Trials as TopicFrailtybusiness.industryGeneral Medicinemedicine.diseaseClinical trialTreatment OutcomeSample size determinationSample SizeEmergency medicinebusiness
researchProduct

Multicenter and all-comers validation of a score to select patients for manual thrombectomy, the DDTA score.

2021

Background Routine manual thrombectomy (MT) is not recommended in primary percutaneous coronary intervention (P-PCI) but it is performed in many procedures. The objective of our study was validating the DDTA score, designed for selecting patients who benefit most from MT. Methods Observational and multicenter study of all consecutive patients undergoing P-PCI in five institutions. Results were compared with the design cohort and the performance of the DDTA was analyzed in all patients. Primary end-point of the analyses was TIMI 3 after MT; secondary endpoints were final TIMI 3, no-reflow incidence, in-hospital mortality and in-hospital major cardiovascular events (MACE). In-hospital prognos…

medicine.medical_specialtymedicine.medical_treatmentMyocardial Infarction030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinecardiovascular diseasesEdetic AcidThrombectomyPrimary angioplastyFramingham Risk Scorebusiness.industryIncidence (epidemiology)Percutaneous coronary interventionGeneral MedicineTreatment OutcomeMulticenter studyCohortCardiology and Cardiovascular MedicinebusinessTIMIMace
researchProduct